Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib …
F Castagnetti, N Testoni, S Luatti… - Journal of clinical …, 2010 - ascopubs.org
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
[PDF][PDF] Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With …
F Castagnetti, N Testoni, S Luatti, G Marzocchi… - …, 2006 - researchgate.net
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib …
F Castagnetti, N Testoni, S Luatti… - Journal of clinical …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib …
F Castagnetti, N Testoni, S Luatti, G Marzocchi… - JOURNAL OF …, 2010 - iris.unina.it
Deletions of the derivative chromosome 9 do not influence the response and the outcome of
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA …
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA …
[引用][C] Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with …
F CASTAGNETTI - J Clin Oncol., 2010 - cir.nii.ac.jp
Deletions of the derivative chromosome 9 do not influence the response and the outcome of
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate : GIMEMA CML …
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate : GIMEMA CML …
Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With …
F Castagnetti, N Testoni, S Luatti… - JOURNAL OF …, 2010 - iris.uniroma1.it
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib …
F Castagnetti, N Testoni, S Luatti… - JOURNAL OF …, 2010 - sfera.unife.it
PURPOSE: Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
[PDF][PDF] Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated With …
F Castagnetti, N Testoni, S Luatti, G Marzocchi… - Hematology, 2006 - academia.edu
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib …
F Castagnetti, N Testoni, S Luatti… - Journal of Clinical …, 2010 - europepmc.org
Purpose Deletions of the derivative chromosome 9 [der (9)] have been associated with a
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
poor prognosis in chronic myeloid leukemia (CML) across different treatment modalities. In …
[引用][C] Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with …
F Castagnetti, N Testoni, S Luatti… - JOURNAL OF …, 2010 - ricerca.uniba.it
Deletions of the derivative chromosome 9 do not influence the response and the outcome of
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA …
chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA …